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InterferonLysyl oxidase acts as both a matrix modifying enzyme and an oncogene suppressor. It is synthesized as a 50-
kDa proenzyme, secreted, and processed into an ∼30 kDa mature, active enzyme and an 18-kDa propeptide.
The tumor suppressive effect of lysyl oxidase appears to be exerted within the cell, so the subcellular
localization of protein forms was investigated. Propeptide-speciﬁc antibody detected 50-kDa proenzyme in
cytoplasmic and nuclear extracts of non-transformed mouse ﬁbroblasts, but free 18-kDa propeptide was not
detected in any extract. Antibody to epitope near the N-terminus of mature lysyl oxidase detected the
proenzyme product in non-transformed cells, and a 30-kDa cytoplasmic protein in both non-transformed
and transformed cells. RNA interference reduced the expression of lysyl oxidase mRNA and 50-kDa
proenzyme in non-transformed cells, but had no effect on 30-kDa protein, indicating that although this
protein displays a lysyl oxidase epitope, it is not derived from lysyl oxidase message. The absence of both free
18-kDa propeptide and mature lysyl oxidase within non-transformed cells suggests that cellular reversion
after restoration of lysyl oxidase gene expression is mediated by the 50-kDa proenzyme within cells.Published by Elsevier B.V.1. IntroductionLysyl oxidase (LOX) is a secreted enzyme that catalyzes the
oxidative deamination of ɛ-amino lysines in collagen and elastin
ﬁbers. The subsequent condensation of the modiﬁed lysine residues
creates the cross-linked ﬁbers characteristic of the mature forms of
these proteins in the extracellular matrix. Increased LOX activity is
found in ﬁbrotic disease of the lung, in atherosclerosis [1], and in
in vitro models of rat hepatic ﬁbrosis [2]. Type IX Ehlers–Danlos
syndrome (occipital horn syndrome) is characterized by a decrease in
LOX protein and mRNA, and LOX activity is decreased in Menkes
syndrome [3,4]. Inhibition of LOX enzyme activity by the inhibitor β-
aminoproprionitrile results in lathyrism [5].
As well as a protein-modifying enzyme, LOX was identiﬁed as a
tumor suppressor [6,7]. LOX mRNA expression is almost completely
lost in mouse NIH 3T3 cells after transformation by c-H-ras, and LOX
mRNA is restored in interferon (IFN)β-reverted cells. LOXmRNA levels
are reduced signiﬁcantly in rodent cells transformed by a variety of
other oncogenes, including v-raf, v-fes, [6] v-src, c-met, v-fms, v-fos,
and c-trk (S. Contente, unpublished observation). Decreased LOX
expression has been reported in ductal breast carcinoma cells [8], in
prostate tumors [9], and in bronchogenic carcinoma [10]. LOX
expression is lost or decreased in human breast and prostate tumor
tissue sections studied by in situ hybridization (R.M. Friedman, D.L.
Buchhagen, unpublished observation). LOX promoter methylation and
loss of heterozygosity have been found in human gastric cancers [11].
LOX is expressed in human cells that do not normally synthesizeB.V.collagen, such as breast ductal epithelium, colonic epithelium,
prostatic epithelium, and neurons (S. Contente, unpublished observa-
tion), suggesting an additional function for this protein.
LOX is synthesized as a 50-kDa proenzyme (proLOX) that is
secreted and then cleaved in the extracellular space by bone
morphogenetic protein 1 to form an active enzyme of about 30 kDa
[12–16]. However, antibody-reactive, enzymatically active 32-kDa LOX
was reported in nuclei isolated from neonatal rat smooth muscle cells
and NIH 3T3 cells [17], and a 30-kDa mature LOX was reported in the
cytoplasm of human epithelial cells [18]. Puriﬁed bovine aorta 32-kDa
protein, labeled with rhodamine, re-entered vascular smooth muscle
cells and NIH 3T3 cells, and concentrated within nuclei [19]. LOX has
been reported to use histone H1 as a substrate in vitro [20], and to
interact speciﬁcally with histones H1 and H2 in vitro [21].
A possible nuclear role for LOX is supported by the report that over
expression of a 32-kDa transgene in COS-7 cells activated transcrip-
tion of a human collagen promoter in a luciferase reporter plasmid
[22]. In addition, injected recombinant 32-kDa LOX also prevented the
p21-H-ras-induced meiotic maturation of Xenopus laevis oocytes [23].
Recently, the18-kDa LOX propeptide, which is generated upon
proteolysis of 50-kDa proLOX in the extracellular space, was expressed
in bacteria and found to inhibit cell cycle progression and growth in
soft agar of ras-transformed cells [24], and the invasive phenotype of a
Her-2/neu cell line was inhibited after introduction of propeptide or
proLOX constructs [25]. The18-kDa propeptide was reported to
localize differently in MC3T3-E1 osteoblasts based on their stage of
differentiation [26].
We prepared afﬁnity puriﬁed, polyclonal antisera raised against
peptides to determine the intracellular distribution of proenzyme,
mature enzyme, and propeptide in non-transformed and ras-
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within the propeptide portion of proenzyme or at the amino terminus
of mature processed enzyme. Only 50-kDa proenzyme, and not
mature LOX or propeptide, was found within non-transformed cells.
Although a 30-kDa cytoplasmic protein was recognized by the
antibody to mature LOX in non-transformed cells, this protein was
unaffected by siRNA that did affect proLOX expression. In addition, this
30-kDa cytoplasmic protein also appeared in transformed cells that do
not express LOX. This protein, therefore, cannot be derived from the
LOX gene. The distribution of proLOX, and the absence of propeptide
and mature enzyme in any cell compartment suggest that the
reversion observed after restoration of LOX gene expression in ras-
transformed cells is associated with the appearance of 50-kDa proLOX
in the nucleus, and that the action of the 18-kDa propeptide region is
exerted as a part of the proenzyme.
2. Materials and methods
2.1. Antibodies
Rabbit polyclonal anti-LOpep3 [27] was afﬁnity puriﬁed (Quality
Controlled Biologicals, Hopkinton, MA) against 170KYSDDNPYYNYYD-
TYCR
186
, the immunogenic peptide. This sequence is located near the
N-terminus of mature LOX, except that residue 185E was replaced by
cysteine. Residues 170–186 (numbering refers to mouse protein) are
identical in mouse and human LOX, and there is no identity with
known human or mouse lysyl oxidase-like proteins [28–33]. Afﬁnity-
puriﬁed anti-LOpep3 was used at a 1:2000 dilution. Rabbit anti-
LOpep4 serum was prepared and afﬁnity puriﬁed against peptide
C-141ASPQPPQLSNLRPPS155 (Quality Controlled Biologicals, Hopkin-
ton, MA). This sequence is located within the 18-kDa propeptide
region of proLOX. Afﬁnity-puriﬁed antiserum was used at a 1:20,000
dilution. Polyclonal antibodies to other LOX epitopes were obtained
from Novus Biologicals, Littleton, CO (NB100-2527, NB100-2528, NB
100-41090, NB110-59729, NB110-41568), and from Santa Cruz
Biotechnology, Santa Cruz, CA (E-19 and V-20). Of these antibodies,
only NB100-2527 and NB110-41568 bound speciﬁcally to in vitro
translated LOX products. The other preparations were not used
further. Secondary antibodies and loading control/compartment-
speciﬁc antibodies were obtained from AbCam, Inc., Cambridge,
MA, and Santa Cruz Biotechnology, Santa Cruz, CA. Antibody beads
were created using 10 μl of afﬁnity puriﬁed anti-LOpep3 and 100 μl
of protein A Dynabeads (Invitrogen, Carlsbad, CA) according to
the manufacturer's instructions. Forty μg of protein extract was incu-
bated with the antibody beads for 1 h at 4 °C, and the beads were
captured by magnet. Supernatant was removed and concentrated
using a Microcon YM-10 cartridge (Millipore, Bedford, MA) prior to
gel analysis.
2.2. Construction of LOX expression clones and transcription–translation
of products
The Gateway System (Invitrogen) was used to generate entry
clones of LOX size species in pDONR221. PCR fragments representing
propeptide (A22-G162), proenzyme (A22-Y411), and mature LOX
(D163-Y411) were generated from plasmid clone Nco12, which
contains a full-length mouse LOX cDNA. PCR primers contained
attB1or attB2 sequences as speciﬁed in the Gateway manual, along
with appropriate start or stop codons plus 18–25 bp of LOX-speciﬁc
nucleotides to create the desired protein. Entry clones pENTRLO18,
pENTRLO30, and pENTRLO50 were subsequently recombined with
mammalian expression vector pcDNA3.2-V5Dest or bacterial expres-
sion vector pDEST14, and used for subsequent experiments. Con-
structs in mammalian expression vectors were expressed by in vitro
transcription and translation using TNT Coupled Wheat Germ Extract
System (Promega Corp., Madison, WI). pDEST14-LO18was transfectedinto Escherichia coli BL21-A1 competent cells, and resultant ampicillin
resistant colonies were cultured and induced with L-arabinose
according to the Gateway protocol. Cells were collected by centrifuga-
tion after 4 h of induction, suspended in 1×SDS-PAGE sample buffer
(Invitrogen), boiled for 5 min, and centrifuged brieﬂy. 10 μl of
supernatant was used for gel electrophoresis.
2.3. Cell culture and transfection
NIH 3T3 is a ﬁbroblast cell line derived from Swiss mouse. RS485 is
NIH 3T3 transformed by c-H-ras [34]. Mouse cell lines and mouse
primary cells were cultured in DMEM+ Glutamax-1 supplemented
with 10% fetal bovine serum (GIBCO). All cells were cultured at 37 °C
in a humidiﬁed 5% CO2 atmosphere. Mouse primary embryo ﬁbroblast
cells PMEF-NL were obtained from Chemicon International (Temicula,
CA), and mouse primary ﬁbroblast cells TGM-1 were cultured using
shared tissue from 1-day old FVB/N mice. For transfections, 5 μg of
endonuclease-free plasmid DNA was introduced into 3.6×105 RS485
cells using Lipofectamine (Invitrogen) for 5 h at 37 °C, 5% CO2, after
which DNA complexes were removed and replaced with DMEM-10%
FBS. Cells were split 1:20 after 48 h, and selection with G418 (500 μg/
ml) was started 24 h after that. Individual G418 resistant clones
selected 10 days later were expanded up into 75 cm2 ﬂasks. For soft
agar assays, 3×104 cells mixed into 3 ml of warm 0.35% agar were
overlaid onto a base of 5ml of 0.7% agar in a 60mmgridded dish. After
10 days of incubation at 37 °C, dishes were stained with 1 ml 0.005%
crystal violet for about 1 h. Colonies were counted in ten random
4 mm2 areas and averaged. For RNA interference, NIH 3T3 cells were
stably transfected with each of four Sure Silencing shRNA plasmids for
Mouse Lox (SuperArray Bioscience Corp, Frederick, MD). Cultures
were selected for neomycin resistance and individual cells were
cloned out. Cellular RNAwas analyzed by northern blot with LOX DNA
probes as previously described [27].
2.4. Protein preparation and immunoblot analyses
Whole cell lysates were prepared using M-PER, and cytoplasmic
and nuclear extracts were prepared using NE-PER (Pierce Biotech-
nology, Rockford, IL). Protein concentration was determined using
BCA Protein Assay kit (Pierce). Puriﬁed bovine heart lysyl oxidase was
a gift from Dr. Herbert Kagan, Department of Biochemistry, Boston
University School of Medicine. Total, cytoplasmic or nuclear cell
extracts (20 μg) were denatured in NuPage sample buffer and
electrophoresed on NuPage 4%–12% Bis–Tris gels in 3-(N-morpho-
lino) propanesulfonic acid (MOPS)-SDS buffer (Invitrogen, Carlsbad,
CA) according to the manufacturer's instructions. MagicMark™ XP
Western Protein Standard (Invitrogen) was used for direct visualiza-
tion of protein standard bands by secondary antibodies. Electro-
phoresed proteins were transferred to Hybond-P membranes (GE
Healthcare) at 35 V for 60 min at 4 °C in a Novex Xcell blot module, or
at 23 V for 4 min in an iBlot Gel Transfer Device (Invitrogen).
Membranes were rinsed in TBST (0.1% Tween-20 in 1.5 M NaCl,
100 mM Tris, pH 8.0) and blocked overnight with rocking at 4 °C in a
blocking buffer of 5% nonfat dry milk in TBST. Membranes were
incubated with primary antibody in blocking buffer with rocking for
2 h at room temperature or at 4 °C overnight, washed three times for
15 min each at room temperature with TBST, incubated with
secondary antibody in blocking buffer for 45 min at room tem-
perature with rocking, and washed as described. Membranes were
developed with ECL Plus (GE Healthcare, Piscataway, NJ) for 5 min.
Digital images were obtained using an LAS-1000 Plus Luminescent
Image Analyzer (Fujiﬁlm Co., Stamford, CT). Film images were
obtained using Hyperﬁlm ECL (GE Biosciences), developed in a
Kodak M35A X-OMAT processor. Membranes to be reprobed were
stripped 15–30 min at 50 °C in Restore (Pierce Biotechnology,
Rockford, IL).
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3.1. Validation of peptide antibody preparations
The speciﬁcity of peptide antisera was veriﬁed by immunoblot
against in vitro transcription–translation products derived from sub-
cloned cDNAs for LOX proenzyme (50-kDa), mature enzyme (30-kDa),
or propeptide (18-kDa). Propeptide product isolated from a bacterial
expression system was also used (Fig. 1A). Anti-LOpep3 (this labora-
tory),which recognizes anepitope at theN-terminus ofmature LOX, and
anti-LOX2527 (Novus), which recognizes an epitope in the central area
of LOX, each detected in vitro products derived from proenzyme and
mature enzyme cDNA clones. As expected, these antisera did not react
with 18-kDa propeptide product (not shown). Anti-LOpep4 (this
laboratory) and anti-LOX41568 (Novus), which were raised to different
epitopes in the propeptide region, detected products from the 50-kDa
proenzyme and 18-kDa propeptide clones. These antibodies did not
recognize the 30-kDa product of the mature enzyme subclone, as
expected. Anti-LOpep3 and anti-LOX2527 each recognized a 30-kDa
protein in a preparation of active LOX puriﬁed from bovine tissue
(Fig. 1B). Thus, LOX enzyme isolated from animal tissue does exhibitFig. 1. Speciﬁcity of anti-peptide antibodies. A. Protein blots of in vitro translated
products of LOX expression clones and bacterial expression product probedwith afﬁnity
puriﬁed antibodies. C, no DNA control translation; 30, product from mature LOX clone;
50, product from proenzyme clone; 18, in vitro translation of propeptide clone; 18b,
propeptide clone bacterial product. Anti-LOpep4 binds non-speciﬁcally to awheat germ
protein slightly smaller than 50-kDa, and anti-LOX41568 binds non-speciﬁcally to a
wheat germ product of about 40-kDa. B. Enzymatically active bovine heart LOX protein
probed with antibodies to mature LOX epitopes. LO, 25 ng bovine LOX preparation; M,
protein size markers.
Fig. 2. 18-kDa propeptide is absent in cells. A. Cytoplasmic (C) and nuclear (N) extracts
of non-transformed (NIH 3T3), ras-transformed (RS485) and primary mouse ﬁbroblast
cells PMEF and TGM-1 probed with propeptide antibody anti-LOpep4. Cytoplasm-
speciﬁc (tubulin) and nuclear-speciﬁc (histone) antibodies were used for loading and
compartment controls. M, protein size markers. B. Twenty and 60 μgram of cytoplasmic
(C) and nuclear (N) extracts of NIH 3T3 and RS485 probed with propeptide antibody
anti-LOpep4. M, protein size markers. C. Extracts as in A. probed with propeptide
antibody anti-LOX 41568.both these epitopes and mature LOX in cell extracts would be expected
to react with both of these antibodies. Each of these four antibodies
recognized the expected epitopes in engineered products and, in the
case ofmature LOXepitopes, the antibodies also recognized LOX isolated
from bovine tissue. It was expected that these antibodies could be used
to provide valid data on LOX expression in studies of cell extracts.
However, as shown below, three of the four antibodies also recognize
cellular proteins that, while close in size to that expected formature LOX
or propeptide, are in fact not derived from proLOX.
Fig. 4. RNA interference reduces LOX message and proenzyme protein. A. RNA blot
probed with LOX DNA probe. GAPDH used as loading control. 1. NIH 3T3; 2. RS485; 3–6.
shRNA clones 2-2A-2, 3-1A-4, 3-1B-14, and 3-1B-17. B. Total protein extracts probed
with the indicated antibody. Actin used as loading control. M, protein size markers. 1.
NIH 3T3; 2. RS485; 3–6. shRNA clones 2-2A-2, 3-1A-4, 3-1B-14, and 3-1B-17.
1275S. Contente et al. / Biochimica et Biophysica Acta 1793 (2009) 1272–12783.2. ProLOX, but not free propeptide, is found within non-transformed
and primary mouse ﬁbroblast cells
The antibody anti-LOpep4, which we prepared to the propeptide
region residues 141–155, detected 50-kDa protein in cytoplasmic
and nuclear extracts of NIH 3T3 and primary mouse ﬁbroblasts (PMEF,
TGM-1) (Fig. 2A). The protein in nuclear extracts migrated slightly
slower, suggesting that nuclear proLOX may be modiﬁed. There was no
50-kDa protein present in ras-transformed RS485, which is consistent
with the lack of LOX mRNA in this cell line [6,7]. However, no proteins
corresponding to the 18-kDa propeptide fragment were detected by
anti-LOpep4 in any cell lines. In cell line 62, a revertant of RS485 induced
with IFNβ and retinoic acid [35], the expression of 50-kDa protein was
restored in both cytoplasm and nucleus (not shown). As with the other
cell lines, no 18-kDa propeptide was detected in the revertant. The lack
of 18-kDa propeptide in both NIH 3T3 and RS485 was veriﬁed using
immunoblotspreparedwith three times theusual amountof extract and
probed with anti-LOpep4 (Fig. 2B). This also veriﬁed the lack of 50-kDa
protein in RS485 extracts. Additionally, material was prepared as
described [26] from the entire nuclei pellet obtained from cultured
cells; immunoblot analysis of this material with anti-LOpep4 revealed
no 18-kDa propeptide in either NIH 3T3 or RS485 (not shown).
As other propeptide antibodies were reported to detect free
18-kDa in cells, we used anti-LOX41568 to verify the lack of 18-kDa
propeptide in mouse cell extracts. This is a commercially available
antibody, raised to propeptide region residues 78–115, which does
recognize bacterial propeptide product (Fig. 1A). This antibody
detected 50-kDa proenzyme in extracts of non-transformed cells,
but not in RS485 extracts, as expected (Fig. 2C). However, this
antibody did recognize an 18-kDa protein in both non-transformed
and transformed cells. This protein, however, although of the expected
size, cannot be the LOX propeptide because it is abundant in the
transformed cells that lack LOX mRNA and 50-kDa proenzyme. In
addition, as both anti-LOpep4 and anti-LOX41568 recognize 18-kDa
propeptide synthesized in bacteria, both should recognize anyFig. 3. Antibodies to epitopes within mature LOX detect different cellular proteins.
Cytoplasmic (C) and nuclear (N) extracts of non-transformed (NIH 3T3), ras-
transformed (RS485) and primary mouse ﬁbroblast (TGM-1) cells were probed with
A. anti-LOpep3 (N-terminal epitope) and B. anti-LOX 2527 (central epitope). M, protein
size markers.propeptide present in cells, and this is not the case. Therefore, we
conclude that there is no free18-kDa propeptide within cells.
3.3. Mature LOX is not found within cells
Anti-LOpep3 was prepared to the sequence KYSDDNPYYNYYD-
TYCR, located at the N-terminus of mature LOX. This antibody
detected both a 50-kDa and a 30-kDa protein in cytoplasmic extracts
of NIH 3T3 and primarymouse ﬁbroblasts (TGM-1) (Fig. 3A). Based on
the published literature that mature LOX is found within cells, this
would appear to be an expected result. Several studies have been
performed using antibody prepared to LOX peptide KYSDDNPYY-
NYYDTYERPRPGG [18,36–38], which is nearly identical to the pep3
sequence. This antibody also recognizes a 50-kDa and a 30-kDa
protein [18,36], and it is reasonable to conclude that both antibodies
recognize the same two proteins. However, cytoplasmic extracts of
ras-transformed RS485 probed with anti-LOpep3 had no 50-kDa
protein, but did have abundant 30-kDa protein (Fig. 3A). As LOX
message is severely down regulated in RS485 and these cells have no
LOX enzyme activity [6,7], little, if any, LOX protein was expected to
appear in these transformed cells. Therefore, while the lack of 50-kDa
protein was not surprising, the presence of an abundant 30-kDa
protein, in the cytoplasm of transformed cells, was unexpected.
Nuclear extracts of NIH 3T3 and TGM-1 did contain 50-kDa protein,
although it was more abundant in TGM-1. No 50-kDa protein was
observed in nuclear extracts of RS485, and 30-kDa protein did not
appear in nuclear extracts of any cell lines. Therefore, anti-LOpep3
recognizes, in addition to proLOX in cytoplasmic and nuclear extracts,
a cytoplasmic protein that could be mature LOX, but which appeared
in cells where mature LOX should not be present.
A second antibody to mature LOX, anti-LOX2527, detected 50-kDa
proLOX in NIH 3T3 and TGM-1 cell extracts, but not in RS485 cell
extracts (Fig. 3B). This was consistent with the expression pattern
Fig. 6. 50-kDa protein displays each LOX epitope. NIH 3T3 cytoplasmic extract was
absorbed against magnetic bead-linked anti-LOpep3, and untreated extract (U) and
absorbed extract (A) were probed with the indicated LOX antibody. M, protein size
markers.
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antibodies recognized the in vitro translated LOX proenzyme.
However, anti-LOX2527 also detected a 32-kDa protein in trans-
formed and non-transformed cell extracts. This protein had a diffe-
rent compartmental distribution. It was predominantly nuclear in
non-transformed cells, and abundant in both compartments of trans-
formed cells. The 30-kDa protein recognized by anti-LOpep3 was
found only in cytoplasmic extracts. The 32-kDa protein was not
recognized by anti-LOpep3, and the 30-kDa cytoplasmic protein was
not recognized by anti-LOX2527. This indicates that the 30-kDa
protein displays the N-terminal LOX epitope, but not the central
epitope, and that the 32-kDa protein displays the central epitope but
not the N-terminal epitope. It was previously shown that both anti-
bodies did recognize puriﬁed bovine LOX (Fig. 1C), thus neither
cellular protein can be mature LOX, even though each displays at
least one LOX epitope. The presence of both of these small cellular
proteins in transformed cells, which do not express proLOX, addi-
tionally supports the conclusion that neither of these small cellular
proteins is true mature LOX. Analysis of secreted LOX using both
antibodies (Section 3.5) also supports this conclusion.
3.4. RNA interference for LOX does not affect 18-kDa or 30-kDa
expression
Fig. 4A shows RNA analysis of four clones obtained after stable
transfection of NIH 3T3withmouse LOX shRNA plasmid #2 or #3. Two
size species of LOX mRNA always appear in normal mouse cells, as
there are two, well-separated polyadenylation signals that are utilized
in this message [39]. There are reduced amounts of LOX mRNA in the
shRNA clones (lanes 3–6) compared to an NIH 3T3 control (lane 1),
and there is almost no LOX mRNA in RS485 (lane 2). The LOX mRNA
signals were quantitated by densitomtery, and normalized to the
GAPDH signals. The LOX mRNA remaining in the shRNA clones was
19%, 15%, 23% and 22% of that expressed in NIH 3T3. RS485 expresses
2% of LOX mRNA compared to NIH 3T3. Fig. 4B presents western
analysis of protein extracted from the shRNA clones. Probing with
anti-LOpep4 revealed a reduction of 50-kDa proenzyme product in
these clones to 6%, 6%, 15% and 19% of that observed in NIH 3T3, but
probing with anti-LOpep3 showed that the amount of 30-kDa protein
in the shRNA clones was not reduced, and that this protein was
actually more abundant in shRNA clones than in NIH 3T3. Thus the 30-
kDa cytoplasmic protein cannot be derived from the LOX gene and it is
not mature LOX. Proenzyme product in shRNA extracts as detected by
anti-LOX41568 was reduced to 40–62% of the amount present in NIH
3T3, and no proenzyme was detected in RS485 (not shown). The
amounts of the 18-kDa protein detected in shRNA extracts and RS485
were 70–95% of the amount of this protein found in NIH 3T3. These
ﬁndings conﬁrm that this 18-kDa protein, although recognized by
antibody anti-LOX41568, cannot be LOX propeptide.Fig. 5.Mature LOX appears only in conditionedmedia. Conditionedmedia fromNIH 3T3
cells was blotted and probed with anti-LOX2527 and anti-LOpep3. Lane 1, NIH 3T3 cell
extract; lane 2, 30 μl of NIH 3T3 conditioned media, concentrated from 0.1 ml on
Centricon YM-10 column. The strongly hybridizing band at ∼55 kDa in lane 2 is
immunoglobulin derived from the fetal bovine serum added to cell culture media.3.5. Protein secreted by NIH 3T3 does bind both anti-LOpep3 and
anti-LOX2527
Conditioned media from NIH 3T3, which contains enzymatically
active, mature LOX enzyme, was assayed by immunoblot with each
antibody (Fig. 5). Each antibody recognized a secreted protein slightly
larger than 30 kDa in conditioned media. In NIH 3T3 cellular extract
run in parallel, it is clear that the small cellular proteins detected are
either slightly larger or slightly smaller than the secreted protein. The
secreted protein was not detected, by either antibody, in conditioned
media from transformed cells (not shown). This was consistent with
the lack of LOX in transformed cells. This N30 kDa extracellular protein
must therefore be mature LOX.
3.6. Antibodies do bind to the same 50-kDa protein
To verify that the antibodies used were recognizing the same
50-kDa protein, NIH 3T3 cytoplasmic extract was absorbed with
magnetic bead-linked anti-LOpep3, and the proteins remaining in the
supernatant were analyzed by immunoblot with anti-LOpep3, anti-
LOpep4, and anti-LOX-2527 (Fig. 6). The 50-kDa band was not
detected by anti-LOpep3 in the absorbed material, indicating that the
50-kDa protein was successfully removed from the extract by the
antibody-linked beads. The 30-kDa protein, although recognized on
immunoblots as a denatured protein, did not bind to anti-LOpep3 in
its native form and was not adsorbed onto the beads. Thus, this
protein appeared in both lanes when anti-LOpep3 was used to probe
the blot. Anti-LOpep4 and anti-LOX 2527 did not detect any 50-kDa
protein in the absorbed material, indicating that all three antibodies
recognize one 50-kDa protein, which does represent LOX proenzyme.
The slight shadow above the 50-kDa position in the absorbed mate-
rial lane represents IgG released from the beads during incubation
with extract.Fig. 7. Expression of proenzyme in cells reverted by transfection. Cytoplasmic (C) and
nuclear (N) extracts of non-transformed, ras-transformed, and reverted lines LO50-3
and LO50-22 (reverted by transfection with proenzyme expression construct), were
probed with anti-LOpep4. M, protein size markers.
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Expression constructs of 50-kDa proenzyme,18-kDa propeptide, or
control plasmid were transfected into RS485 cells and geneticin-
resistant clones were selected. Two of the 18 resistant clones obtained
with the proenzyme construct expressed a 50-kDa protein (Fig. 7),
and each of these had a 99% reduction in colony formation in soft agar
as compared to RS485. The colonies that did form were signiﬁcantly
smaller than control RS485 colonies, and were similar in size to the
few colonies that are observed with NIH 3T3 (95% reduction in colony
formation compared to RS485). Revertant LO50-3 exhibits two extra
bands, of about 35- and 40-kDa in cytoplasmic extracts. In ras-
revertants generated by both IFN-RA treatment and by stable
transfection with proLOX expression clones, we consistently see
these extra bands in the cytoplasm along with the restoration of 50-
kDa proLOX. Thus, we do not believe these bands are an artifact of
either treatment. The extra bands disappear, along with 50-kDa
proLOX, when revertants are retransformed by treatment with
5-azacytidine (T.J. Yeh, unpublished results).
Five other proenzyme clones had a faint signal for 50-kDa protein,
but colony formation in soft agar for these clones was unaffected
compared to RS485. There was no free 18-kDa propeptide detected in
any of the clones created with the proenzyme construct. Of 27
resistant lines obtained with propeptide construct, none expressed an
18-kDa product. Four randomly chosen clones from this group showed
no reduction of colony formation in soft agar. All 13 control plasmid
clones were negative for 50-kDa or 18-kDa products, and none of the
four randomly chosen control clones had reduced colony formation in
soft agar.
4. Discussion
LOX functions both as an enzyme that cross links extracellular
matrix proteins and as a tumor suppressor. Recent work suggests that
the tumor suppressor function of LOX is exerted inside the cell, most
likely in the nucleus. Our studies show that only the 50-kDa
proenzyme is present in cytoplasmic and nuclear extracts of primary
mouse ﬁbroblasts and cell line NIH 3T3, and that, in contrast to
previously published results [17,18,26], mature LOX and free 18-kDa
propeptide are not found within cells.
The lack of proLOX in the ras-transformed cell line, the reappear-
ance of this protein in mouse revertant lines induced by interferon-
retinoic acid combination treatment, and the lack ofmature LOXor LOX
propeptidewithin non-transformed cells strongly suggest that it is the
proenzyme form of the protein that is responsible for reversion. The
18-kDa propeptide region of LOX, whether supplied as a bacterially
produced protein, or introduced into cells as an expression construct,
was shown to inhibit transformed cell growth and tumor formation
[24,25]. While we were able to generate two lines of transformed
RS485 cells expressing 50-kDa proenzyme, with resultant inhibition
of cell growth in soft agar, none of the cell lines transfected with the
18-kDa propeptide construct expressed the propeptide protein.
Therefore, we were unable to verify that the propeptide is sufﬁcient
for inhibiting cell growth in ras-transformants.
We did not detect the 18-kDa propeptide as a discrete entity in
either cytoplasmic or nuclear extracts of primary cells or non-
transformed cell lines using our propeptide antibody anti-LOpep4.
This antibody was successful in detecting 50-kDa proLOX in cell
extracts, as well as in vitro translated proLOX or 18-kDa propeptide,
and an 18-kDa propeptide clone expressed in bacteria. Propeptide
antibody anti-LOX41568, raised to a different epitope, also detected
the in vitro translated LOX products as expected. However, while this
antibody detects 50-kDa proLOX in non-transformed cells, it also
detects an 18-kDa protein in non-transformed and transformed cells.
RNA interference for LOX reduced the amount of proLOX, but not the
amount of 18-kDa protein detected with anti-LOX41568, indicatingthat the 18-kDa protein recognized by anti-LOX41568 is not LOX
propeptide. Thus, we believe that the failure of our propeptide region
antibody, anti-LOpep4, to detect 18-kDa propeptide in these cell
extracts reﬂects the absence of 18-kDa propeptide in these extracts.
Accordingly, while the tumor suppressor activity in proLOX can be
mapped to the propeptide region, it is the entire 50-kDa proLOX, not a
separate 18-kDa propeptide fragment, which functions in the nucleus
as a growth regulator when ras-transformed mouse ﬁbroblasts are
reverted by restoration of lysyl oxidase gene expression. The 18-kDa
protein did appear as a doublet in RS485 and LOX shRNA clones, so it is
possible that expression of this protein is related to the reduced
expression of LOX.
A 30-kDa cytoplasmic protein that was recognized by antibody to
mature LOX N-terminus, and a 32-kDa protein recognized by antibody
to a central LOX epitope were both abundant in ras-transformed cells
as well as in non-transformed cells. This suggested that neither of
these two small proteins was mature LOX, as ras-transformed cells are
transcriptionally down regulated for LOX expression, have no LOX
enzymatic activity, and do not express proenzyme. RNA interference
studies conﬁrmed that 30-kDa cytoplasmic protein is not derived from
the LOX gene. The 30-kDa protein was upregulated in the LOX shRNA
clones. The 30-kDa, 32-kDa and 18-kDa proteins are abundantly
expressed in non-transformed cells as well, and many proteins are
upregulated after ras transformation. These proteins could be LOX
related; each certainly contains an epitope that reacts with one of the
LOX antibodies. But, at present, it is clear only that these proteins are
not derived from LOX mRNA.
We have observed consistently that the mature region antibodies
do not bind proLOX as well as do the propeptide region antibodies.We
have determined that both mature region antibodies and our
propeptide antibody (LOpep4) do bind to the same 50-kDa proLOX
protein (Fig. 6). As each mature region antibody also cross-reacts with
a different cellular protein, we do not plan to use these preparations
for any future in situ studies of LOX. We do hope to develop a
completely speciﬁc antibody for mature LOX.
The ﬁnding that mature LOX is not an intracellular protein
underscores the importance of using independent antisera to at
least two epitopes for unambiguous identiﬁcation of proteins.
Previous conclusions about the presence and role of mature LOX
and free propeptide within cells should be evaluated in light of the
ﬁndings presented here. The three small, non-LOX proteins are
abundant in transformed cell lines, and each binds with one of three
anti-LOX preparations. In situ studies using such preparations could
lead to incorrect conclusions about the expression of LOX or
propeptide in tumor tissues.Acknowledgements
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